ArticleCommunications medicine2021
Understanding genetic risk factors for common side effects of antidepressant medications.
Article in Communications medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Antidepressant and antipsychotic side-effects and personalised prescribing: a systematic review and digital tool development.The lancet. Psychiatry · 2023Pooled it
- Efficacy and Safety of Ammoxetine in Major Depressive Disorder: A Randomized Clinical Trial.JAMA network open · 2025Trial
- Azetukalner, a Novel KV7 Potassium Channel Opener, in Adults With Major Depressive Disorder: A Randomized Clinical Trial.JAMA network open · 2025Trial
- The effect of drug holidays on sexual dysfunction in men treated with selective serotonin reuptake inhibitors (SSRIs) other than fluoxetine: an 8-week open-label randomized clinical trial.BMC psychiatry · 2024Trial
- Applying the Behavioural Science Approach to Realist Reviews and Evaluations (BARR/E): A Protocol for a Review of Antidepressant Deprescribing Interventions in Primary Care.Behavioral sciences (Basel, Switzerland) · 2026Article
- Understanding antidepressant change patterns in the UK Biobank.The British journal of psychiatry : the journal of mental science · 2026Article
- PGS Browser: a public platform for personalized polygenic score analysis and interpretation.Nature communications · 2026Article
- CGRP-targeted therapy fulfilling the treatment gap in medication-underuse setting: a retrospective cohort study at a tertiary headache center in Thailand, a lower-middle-income country.The journal of headache and pain · 2025Article
- Genetic influences on antidepressant side effects: a CYP2C19 gene variation and polygenic risk study in the Estonian Biobank.European journal of human genetics : EJHG · 2025Article
- Article
- Appraisal of multiple polygenic risk scores to estimate the risk of myocardial infarction and coronary artery lesions.Communications medicine · 2025Article
- Sociodemographic, clinical, and genetic factors associated with self-reported antidepressant response outcomes in the UK Biobank.Psychological medicine · 2025Article
- GLX351322-Loaded Nanoparticles Alleviate Chronic Stress-Induced Depressive Behaviors Through Inhibition of Ferroptosis and Oxidative Stress.International journal of nanomedicine · 2025Article
- Protocol for a systematic review and meta-analysis on the effects of cold-water exposure on mental health.Frontiers in psychiatry · 2025Article
- The short-term effectiveness of antidepressants in a transdiagnostic sample and determinants of side effects and medication nonadherence: an observational study.Frontiers in psychiatry · 2025Article
- Interventional Psychiatry in India: Bridging Treatment Gaps and Expanding Horizons in Mental Health.Indian journal of psychological medicine · 2024Article
- Parkinson's Disease Polygenic Risk Score and Neurological Involvement in Carriers of the FMR1 Premutation Allele: A Case for Genetic Modifier.Molecular genetics & genomic medicine · 2024Article
- Identifying the most critical side effects of antidepressant drugs: a new model proposal with quantum spherical fuzzy M-SWARA and DEMATEL techniques.BMC medical informatics and decision making · 2024Article
- Effect of bariatric surgery on nutritional and metabolic parameters: does the type of antidepressant medication matter?Eating and weight disorders : EWD · 2024Article
- Exploring the Feasibility of Estrogen Replacement Therapy as a Treatment for Perimenopausal Depression: A Comprehensive Literature Review.Medicina (Kaunas, Lithuania) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Major depression is one of the most disabling health conditions internationally. In recent years, new generation antidepressant medicines have become very widely prescribed. While these medicines are efficacious, side effects are common and frequently result in discontinuation of treatment. Compared with specific pharmacological properties of the different medications, the relevance of individual vulnerability is understudied. Methods: We used data from the Australian Genetics of Depression Study to gain insights into the aetiology and genetic risk factors to antidepressant side effects. To this end, we employed structural equation modelling, polygenic risk scoring and regressions. Results: Here we show that participants reporting a specific side effect for one antidepressant are more likely to report the same side effect for other antidepressants, suggesting the presence of shared individual or pharmacological factors. Polygenic risk scores (PRS) for depression associated with side effects that overlapped with depressive symptoms, including suicidality and anxiety. Body Mass Index PRS are strongly associated with weight gain from all medications. PRS for headaches are associated with headaches from sertraline. Insomnia PRS show some evidence of predicting insomnia from amitriptyline and escitalopram. Conclusions: Our results suggest a set of common factors underlying the risk for antidepressant side effects. These factors seem to be partly explained by genetic liability related to depression severity and the nature of the side effect. Future studies on the genetic aetiology of side effects will enable insights into their underlying mechanisms and the possibility of risk stratification and prophylaxis strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.